According to current scientific evidence, whereas IL-17 inhibition exacerbates inflammatory bowel disease, IL-23 inhibitors demonstrated clinical improvement and so they indicated in the case of co-existence of Chron Disease [143,144]. Here, IL17A is linked to inflammatory bowel disease.